Valuation: Axsome Therapeutics, Inc.

Capitalization 830.37Cr 715.95Cr 646.29Cr 620.13Cr 1.13TCr 76TCr 1.18TCr 7.64TCr 3.06TCr 37TCr 3.12TCr 3.05TCr 1,30900Cr P/E ratio 2026 *
-189x
P/E ratio 2027 * 26.4x
Enterprise value 809.56Cr 698Cr 630.09Cr 604.59Cr 1.1TCr 74TCr 1.15TCr 7.45TCr 2.98TCr 36TCr 3.04TCr 2.97TCr 1,27600Cr EV / Sales 2026 *
8.19x
EV / Sales 2027 * 5.12x
Free-Float
81.71%
Yield 2026 *
-
Yield 2027 * -
1 day+0.54%
1 week-0.95%
Current month-0.95%
1 month-11.08%
3 months+8.79%
6 months+29.69%
Current year-11.12%
1 week 158.41
Extreme 158.41
168
1 month 158.41
Extreme 158.41
187.18
Current year 158.41
Extreme 158.41
191.5
1 year 86.99
Extreme 86.99
191.5
3 years 53.71
Extreme 53.71
191.5
5 years 19.38
Extreme 19.38
191.5
10 years 1.94
Extreme 1.94
191.5
Manager TitleAgeSince
Chief Executive Officer 57 12/01/2012
Director of Finance/CFO 51 16/05/2018
Chief Operating Officer 42 01/04/2014
Director TitleAgeSince
Chairman 57 12/01/2012
Director/Board Member 64 01/12/2014
Director/Board Member 58 01/12/2014
Change 5d. change 1-year change 3-years change Capi.($)
+0.54%-0.95%+32.87%+155.64% 830.37Cr
-0.66%-2.79%+7.40%-1.81% 7.8TCr
-2.68%-0.52%+33.16%+214.46% 5.54TCr
-0.18%+64.40%+64.40%+64.40% 5.12TCr
-0.15%-0.33%-43.67%-50.73% 4.94TCr
-1.71%-3.62%+22.94%-30.21% 2.71TCr
-2.43%-1.96%+47.49%-62.76% 2.07TCr
-1.43%-5.26%+35.53%+28.99% 1.91TCr
+6.18%-2.12%+107.21%+97.16% 1.85TCr
-1.21%-4.75%+27.92%+56.07% 1.41TCr
Average -0.37%-3.00%+33.52%+47.12% 3.42TCr
Weighted average by Cap. -0.70%-2.94%+24.84%+43.44%

Financials

2026 *2027 *
Net sales 99Cr 85Cr 77Cr 74Cr 134.55Cr 9.08TCr 140.81Cr 909.05Cr 364.19Cr 4.35TCr 370.81Cr 362.9Cr 16TCr 153.37Cr 132.24Cr 119.37Cr 114.54Cr 208.86Cr 14TCr 218.59Cr 1.41TCr 565.35Cr 6.76TCr 575.62Cr 563.35Cr 24TCr
Net income -4.68Cr -4.04Cr -3.64Cr -3.5Cr -6.38Cr -430.29Cr -6.67Cr -43Cr -17Cr -206.35Cr -18Cr -17Cr -737.98Cr 33Cr 28Cr 26Cr 25Cr 45Cr 3.03TCr 47Cr 303.1Cr 121.43Cr 1.45TCr 123.63Cr 121Cr 5.19TCr
Net Debt -21Cr -18Cr -16Cr -16Cr -28Cr -1.91TCr -30Cr -191.51Cr -77Cr -917.29Cr -78Cr -76Cr -3.28TCr -44Cr -38Cr -35Cr -33Cr -61Cr -4.09TCr -63Cr -409.24Cr -163.95Cr -1.96TCr -166.93Cr -163.37Cr -7.01TCr
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Employees
925
Date Price Change Volume
06/26/06 162.33 $ +0.54% 3,86,982
05/26/05 161.46 $ -1.60% 4,96,030
04/26/04 164.08 $ +0.02% 4,28,787
03/26/03 164.05 $ -1.40% 6,17,604
02/26/02 166.38 $ +1.52% 5,66,830
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
162.33USD
Average target price
222.47USD
Spread / Average Target
+37.05%

Quarterly revenue - Rate of surprise